Photo taken from Fadi Haddad/X
Mar 10, 2024, 12:31
Fadi Haddad: P1/2 study of pivekimab
Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:
“Out in The Lancet Oncology.
P1/2 study of pivekimab.
CD123-ADC
N=91 with R/R AML
RP2D=0.045 mg/kg q3w
TRAEs=FN, infusion reaction, anemia
ORR=21%; CRc=17%
Next step=AZA/VEN/pivekimab.”
Source: Fadi Haddad/X